Accelerating Innovative Medicines: Access Consortium's 2026 Plan
The MHRA-led Access Consortium unveils its 2026 action plan to enhance work-sharing, streamline approvals, and improve patient access to cutting-edge medicines across member nations.
The Access Consortium, led by the Medicines and Healthcare products Regulatory Agency (MHRA), has unveiled its ambitious 2026 action plan aimed at accelerating the development and approval of innovative medicines for patients across member countries. The key priorities of this plan include deepening collaboration, streamlining work-sharing processes, and expediting safe and high-quality drug access.
At the heart of the Access Consortium's strategy is a commitment to enhancing regulatory work-sharing among participating nations. By aligning assessment practices and harmonizing data requirements, the consortium seeks to reduce duplicative efforts and accelerate the review timeline for new drug applications. This harmonization will enable member states to collectively leverage their expertise and resources, ultimately delivering treatments to patients faster.
{{IMAGE_PLACEHOLDER}}Source: UK Government
